Urothelial Carcinoma Clinical Trials in Commack, New York
11 recruitingCommack, New York
Showing 1–11 of 11 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled124 locationsNCT06770582
Recruiting
Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer372 enrolled223 locationsNCT04879329
Recruiting
Phase 2
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center23 enrolled10 locationsNCT05239624
Recruiting
Phase 1
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Urothelial CarcinomaDiffuse Pleural MesotheliomaGastroesophageal Carcinoma
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07532902
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Muscle-invasive Urothelial Carcinoma
Hoffmann-La Roche362 enrolled107 locationsNCT06534983
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
NRG Oncology486 enrolled211 locationsNCT07097142
Recruiting
Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Infiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial Carcinoma
Alliance for Clinical Trials in Oncology271 enrolled424 locationsNCT03609216
Recruiting
Phase 2
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center24 enrolled8 locationsNCT05868265
Recruiting
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Urothelial CarcinomaMetastatic Urothelial CarcinomaNeuropathy
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT07390617